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ABSTRACT
CD47, expressed on a variety of tumor cells, confers immune resistance by 
delivering an inhibitory “don’t eat me” signal to phagocytic cells via its myeloid-specific 
receptor SIRPα. Recent studies have shown that blocking the CD47-SIRPα axis with 
CD47-directed antibodies or antibody-derivatives enhances phagocytosis and increases 
antitumor immune effects. However, CD47 expression on healthy cells creates an 
antigen sink and potential sites of toxicity, limiting the efficacy of CD47-directed 
therapies. In this study, we first characterized CD47 expression in Acute Myeloid 
Leukemia (AML) patients (n = 213) and found that CD47 is highly expressed on both 
AML bulk and stem cells irrespective of the disease state. Furthermore, to inhibit 
the CD47-SIRPα signaling pathway at the tumor site, we developed a so-called local 
inhibitory checkpoint monoclonal antibody (licMAB) by grafting the endogenous SIRPα 
domain to the N-terminus of the light chain of an antibody targeting CD33, a surface 
antigen expressed in AML. LicMABs selectively bind CD33-expressing cells even in the 
presence of a large CD33-negative CD47-positive antigen sink, stimulate phagocytosis 
of AML cells and eliminate AML cell lines and primary, patient-derived AML cells. Our 
findings qualify licMABs as a promising therapeutic approach to confine the benefit 
of disrupting the CD47-SIRPα axis to tumor antigen-expressing cells.
INTRODUCTION
The use of monoclonal antibodies (mAbs) has 
become an important and promising approach in cancer 
immunotherapy [1]. Their clinical success is based on 
their ability to specifically bind to antigens differentially 
expressed in cancer cells and to simultaneously recruit 
immune effector cells via interaction with their Fc 
receptors (FcRs). This triggers immune cell activation, 
including antibody-dependent cellular cytotoxicity 
(ADCC) and antibody-dependent cellular phagocytosis 
(ADCP) [2]. 
Recent studies suggest that a highly promising 
strategy for treating different types of cancers involves 
targeting not only the tumor cell but also immune 
checkpoints, which comprise a plethora of inhibitory 
pathways fundamental for the maintenance of 
self-tolerance under normal physiological conditions 
[3, 4]. It is well documented that tumor cells often 
utilize these immune checkpoints as a mechanism to 
escape immune recognition and gain immune resistance, 
demonstrating the necessity of target these molecular 
pathways [5]. 
CD47 is a transmembrane protein ubiquitously 
expressed on normal cells. Its receptor, the signal 
regulatory protein alpha (SIRPα), is expressed on 
phagocytic cells, including macrophages and dendritic 
cells (DCs). Upon binding to CD47, SIRPα transmits a 
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“don’t eat me” signal that inhibits phagocytosis, thus 
preventing normal host cells from being cleared by 
macrophages [6, 7]. However, it has been shown that 
the disruption of CD47-SIRPα interaction by a blocking 
antibody against human CD47 (B6H12.2) enables 
phagocytosis of Acute Myeloid Leukemia Stem Cells 
(AML LSC) and Acute Lymphoid Leukemia (ALL) cells 
in vitro and inhibits tumor engraftment in vivo [8, 9]. 
Moreover, B6H12.2 repressed tumor growth or cured solid 
tumors in mouse studies [10]. Additionally, a humanized 
IgG4 antiCD47 antibody (Hu5F9-G4) was pre-clinically 
evaluated and entered phase I trials (NCT02216409) 
in patients with AML and solid tumors in 2014 [11]. 
Hu5F9-G4 showed a potent enforcement of phagocytosis 
of primary human AML cells in vitro and an elimination 
of patient-derived AML xenografts in vivo. Furthermore, 
B6H12.2 and Hu5F9-G4 have been shown to synergize 
with tumor-specific monoclonal antibodies such as 
rituximab, an antiCD20 antibody, leading to inhibition of 
engraftment of Non-Hodgkin Lymphoma (NHL) and cure 
of xenografted mice [11, 12]. 
Nevertheless, the ubiquitous expression of CD47 on 
healthy cells, such as red blood cells (RBCs), which are 
abundant and accessible within the bloodstream, might 
create a large antigen sink and potential sites of toxicity 
based on unintended binding. The unwanted binding 
of CD47 on healthy cells could thus be minimized by 
reducing the binding strength for CD47 [13]. As the native 
interaction between SIRPα and CD47 is rather weak 
[14–16], the endogenous extracellular N-terminal domain 
of SIRPα, consisting of an immunoglobulin superfamily 
V-like fold [15, 16], is an attractive alternative to interfere 
with the CD47-SIRPα axis while avoiding the mentioned 
risks [17]. In agreement with this, TTI-621, a SIRPα-Fc 
fusion protein that uses the endogenous SIRPα domain to 
block the CD47-SIRPα axis, was developed by Trillium 
Therapeutics and is currently being evaluated in phase I 
trials for hematologic malignancies (NCT02890368).
CD33, a sialic acid-dependent cytoadhesion 
molecule, is a validated target in AML [18]. Its expression 
on AML cells and AML LSCs [18, 19] has made it the 
target antigen of choice for several antibody-based 
approaches, including mAbs, antibody-drug conjugates 
(ADC), bispecific T-cell engagers (BiTE), bispecific killer 
cell engagers (BiKE) and single-chain variable fragment 
triplebodies (sctbs) [20–27]. Albeit promising results 
were obtained in pre-clinical and clinical investigations of 
several therapeutic formats, no CD33-targeting agent have 
been yet accepted by none of the Medicine Regulatory 
Authorities. Thus, new CD33-directed strategies are 
needed in order to exploit its full potential.
Similarly to CD33, CD47 is overexpressed on AML 
bulk cells and AML LSCs [8, 28]. Expression of CD47 
contributes to tumor progression by enabling AML cells to 
evade phagocytosis and is consequently correlated with a 
poor prognosis [8]. Hence, disruption of the CD47-SIRPα 
interaction might represent a therapeutic strategy in AML 
to induce clearance of tumor cells. 
Here, we report the development and 
characterization of a new antibody format, hereafter 
called a local inhibitory checkpoint monoclonal 
antibody (licMAB). LicMABs were created by grafting 
the endogenous N-terminal Ig domain of SIRPα onto 
the variable light chain of a CD33-targeting IgG1 
antibody scaffold, similar to the recently published 
“SIRPabodies” [17]. We suggest that the resulting licMAB 
blocks the CD47-SIRPα interaction at the site of tumor 
antigen-expressing cells. In other words, by targeting the 
tumor antigen CD33, the blockade of the “don’t eat me” 
signal and therefore the antitumor activity, is restricted 
to CD33-expressing cells. Moreover, we propose that 
the blockade of CD47-SIRPα signaling can be enhanced 
by fusing a second SIRPα domain (resulting in a double 
SIRPα licMAB), thus increasing the local SIRPα 
concentration. 
SIRPα-antiCD33 and 2xSIRPα-antiCD33 licMABs 
were evaluated based on their binding specificity, 
cytotoxic effect and phagocytosis of AML cells in vitro. 
LicMABs successfully stimulate phagocytosis of human 
AML cell lines and enforce elimination of human AML 
cell lines and primary, patient-derived AML cells. Thus, 
our studies establish licMABs as a possible therapeutic 
approach to locally deliver the benefit of CD47-SIRPα 
blockade to tumor cells.
RESULTS
CD47 is highly expressed on bulk AML cells and 
AML LSCs independent of disease state
By expressing CD47, AML cells trigger the “don’t 
eat me” signal to macrophages via SIRPα engagement 
and can therefore escape the immune system by inhibiting 
phagocytosis. Accordingly, previous studies have shown 
that CD47 is expressed at higher levels on AML LSCs 
than on their normal counterparts and it also correlates 
with poor clinical outcomes [8]. To further characterize 
CD47 expression on AML cells, we analyzed 213 AML 
patient samples; 182 of whom were newly diagnosed and 
31 of whom in relapse (Figure 1).
CD47 expression could be detected on 99.8 % of 
bulk SSClow/CD45dim AML cells from the 213 patient 
samples (Figure 1A). Despite considerable inter-patient 
heterogeneity, expression levels of CD47 were consistently 
high, resulting in a Median Fluorescence Intensity (MFI) 
ratio of 48.83 (Figure 1B).
After characterizing CD47 expression on bulk AML 
cells, we sought to evaluate the expression level of CD47 
on AML LSCs, which are found within the CD34+/CD38-
compartment of SSClow/CD45dim cells and are believed to 
be the source of AML relapse. Although the expression 
level of CD47 was significantly lower on AML LSCs 
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with respect to bulk AML cells, the expression level 
was high in both cell compartments (MFI ratios of 48.07 
and 32.31, respectively) (Figure 1C). Furthermore, we 
compared the expression level of CD47 on bulk and AML 
LSCs at the time of initial diagnosis (ID) and relapse. 
Notably, the expression of CD47 did neither differ for 
bulk, nor for AML LSCs, between the two disease states 
(Figure 1D). MFI ratios of CD47 expression on bulk AML 
cells corresponded to 48.67 at ID and 50.04 after relapse, 
and 32.31 and 32.01 on AML LSCs (ID and relapse, 
respectively).
Collectively, these results confirm that CD47 is 
highly expressed on both bulk AML cells and AML LSCs. 
Most interestingly, CD47 expression in AML patients 
appears to be independent of the disease state.
Generation and characterization of licMABs
To locally interfere with the CD47-SIRPα axis at 
the tumor site, we generated the so-called local inhibitory 
checkpoint monoclonal antibodies (licMABs), which 
consist of the endogenous SIRPα V-like domain linked 
to a mAb targeting CD33, a validated target antigen in 
AML [29] (Figure 2). The variable fragment of the 
antiCD33 antibody clone hP67.7 was grafted onto 
an IgG1 scaffold and served as basis for generating 
licMABs. To create the SIRPα-antiCD33 licMAB, the 
N-terminal Ig V-like domain of SIRPα was linked by a 
flexible polyglycine-serine linker (G4S) of 4 repeats to 
the N-terminus of the antiCD33 light chain (Figure 2B). 
A second SIRPα domain was linked by a (G4S)4 linker 
to the N-terminus of the SIRPα-antiCD33 light chain to 
obtain the 2xSIRPα-antiCD33 licMAB (Figure 2C). For 
generation of the antiCD33 mAb, a PreScission protease 
cleavage site was inserted between the SIPRα domain and 
the antiCD33 light chain (Figure 2A). 
SIRPα-antiCD33 licMAB, 2xSIRPα-antiCD33 
licMAB and antiCD33 mAb were produced in Expi293F 
cells and purified by Protein A affinity chromatography 
with yields of 83.5, 67.5 and 31 mg/L of culture medium, 
Figure 1: CD47 is highly expressed on bulk AML cells and AML LSCs irrespective of the disease state. (A) Percentage of 
CD47 positive cells of SSClow/CD45dim bulk AML cells from 213 AML patients. (B) CD47 expression levels (MFI ratio) on SSClow/SSClow/
CD45dim bulk AML cells (n = 213). (C) Comparison of CD47 MFI ratio between SSClow/CD45dim bulk AML cells and CD34+/CD38-  AML 
LSCs (n = 213). (D) Comparison of CD47 MFI ratio at initial diagnosis (ID) and relapse in SSClow/CD45dim bulk AML cells (n = 182 
ID; = 31 relapse) and CD34+/CD38-  LSCs (n = 106 ID; = 20 relapse). Statistical differences were assessed by the Mann-Whitney U test 
(p-value < 0.0001****).
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respectively. Further purification of the proteins by size 
exclusion chromatography confirmed the proteins integrity 
with no significant aggregation, protein degradation or 
contamination (Figure 2A–2C). Two equimolar bands 
were visible in SDS-PAGE analysis for all molecules, 
corresponding to the computed masses of 49.0 kDa for 
the heavy chain and 38.7, 53.3, and 24.0 kDa for the 
SIRPα, 2xSIRPα and antiCD33 light chain, respectively 
(Figure 2D). Further measurements by fluorescence 
thermal shift assays revealed a melting point of 68.5°C 
for the antiCD33 mAb, whereas the melting temperature 
was reduced to 66°C when the SIRPα domain was present 
(Figure 2E). Taken together, these results show that 
licMAB molecules can be produced with a high yield and 
purity and that they are stable at elevated temperatures.
LicMABs bind to CD33 with high affinity and 
weakly interact with CD47 
To evaluate the ability of licMABs to bind to CD33 
and CD47 antigens, four different cell lines were used. The 
CD33- and CD47-expressing AML cell line MOLM-13 
was the main cell line used in this work. SEM, a CD33 
negative, CD47 positive B-lineage Acute Lymphoid 
Leukemia (ALL) cell line, was used to study SIRPα-CD47 
interactions independent of CD33 binding. Flp-INTM-CHO 
cells were stably transfected to generate CD33 or CD47 
single positive cell lines (here designated as CHO_CD33 
and CHO_CD47) and were used as a control for the 
binding studies. Notably, CD33 and CD47 expression 
levels differ between these cell lines (Figure 3A). CD47 
is expressed 3.3-fold higher on SEM cells and 68.8-fold 
higher on CHO_CD47 cells than on MOLM-13 cells, and 
CD33 expression is 4.4-fold higher on CHO_CD33 than 
on MOLM-13 cells. 
All molecules bound comparably to the CD33 and 
CD47 double positive MOLM-13 cell line, irrespective 
of the presence of the SIRPα domain (Figure 3B). In 
addition, a comparable staining intensity was detected 
for all molecules on CHO_CD33 cells, indicating that the 
SIRPα domain does not interfere with CD33 recognition 
and binding. Since SEM cells do not express CD33, no 
binding was observed for the antiCD33 mAb. However, 
we detected a minimal staining signal for the SIRPα-
antiCD33 licMAB (MFI ratio = 1.5) on SEM cells, which 
was increased for 2xSIRPα-antiCD33 licMAB (MFI 
ratio = 2.81), in comparison to the antiCD33 mAb (MFI 
ratio = 1). This result is due to a weak binding of the SIRPα 
domain to CD47 expressed on SEM cells (Figure 3B). To 
assess the binding capability of the single and tandem 
SIRPα domains, we used the engineered CHO_CD47 
cell line. Presumably because of the very high surface 
expression of CD47, both licMABs showed an identical 
staining pattern on CHO_CD47 cells. Consequently, the 
strength of CD47 binding positively correlates with the 
quantity of SIRPα domains present within the licMAB and 
the numbers of CD47 molecules present on the target cell 
surface. 
To quantitatively compare the binding strength of 
each molecule to MOLM-13 cells, we determined KD 
values by avidity measurements using calibrated flow 
cytometry. SIRPα-antiCD33, 2xSIRPα-antiCD33 and 
antiCD33 antibodies showed affinity values in the low 
nM range, consistent with other CD33-targeting agents 
(Figure 3C) [21, 24, 25]. Moreover, the similarity of the 
KD values obtained for all three molecules confirmed 
that tumor antigen-binding is not strongly influenced by 
the presence of the SIRPα domain or its interaction with 
CD47. The affinity of SIRPα for CD47 could not be 
quantified by flow cytometry due to the weak CD47-SIRPα 
interaction. However, µM affinities between CD47 and 
SIRPα have been described in previous studies [15, 16]. 
We hypothesized that the high affinity for CD33 
of the licMABs would facilitate preferred tumor 
antigen-binding over healthy CD47-expressing cells. 
RBCs, which express CD47 [7], are a likely antigen 
sink as they are highly abundant and accessible in the 
bloodstream. To test whether licMABs selectively bind 
CD33 and CD47 double positive cells in the presence of 
RBCs, MOLM-13 cells were mixed with a 5-, 10- or 20-
fold excess of RBCs and analyzed for licMAB binding 
by flow cytometry. To exclude that the binding ability 
of licMABs is resulted from the fact that MOLM-13 
express Fc receptors on their surface and RBCs are Fc 
receptor free, a human IgG1 isotype control was included 
in the assay. The human IgG1 isotype control did neither 
bind to MOLM-13 cells nor RBCs (Supplementary 
Figure S1), whereas the antiCD33 mAb and licMABs 
preferentially bound to MOLM-13 cells even in the 
excess of RBCs. Interestingly, the presence of a second 
SIRPα domain on the licMAB did not influence the 
binding to RBCs compared to the SIRPα-antiCD33 
licMAB (Figure 3D). A high affinity antiCD47 antibody 
(clone B6H12), which served as a control favorably 
bound to RBCs in all conditions. These results confirm 
our hypothesis that licMAB binding is dictated by the 
high affinity targeting to CD33 and not influenced by the 
presence of CD47 on healthy cells.
LicMABs internalize upon bivalent CD33 
binding
Since bivalent mAbs against CD33, and specifically 
the antiCD33 antibody clone P67.6, were shown to 
internalize upon cross-linking [30–32], we tested the 
CD33-targeting licMABs for internalization. To this end, 
CD33 and CD47 double positive MOLM-13 cells were 
incubated with licMABs and mAb and internalization 
was determined by flow cytometry based on the signal of 
the secondary antibody. SIRPα-antiCD33 and 2xSIRPα-
antiCD33 licMABs, as well as the antiCD33 mAb, 
exhibited a similar internalization rate, increasing over 
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Figure 2: Generation and characterization of licMAB molecules. (A–C, left) Schematic representation of antiCD33 mAb, 
SIRPα-antiCD33 licMAB, 2xSIRPα-antiCD33 licMAB and the corresponding light chain engineered vectors (VL, variable light chain; CL, 
constant light chain). (A-C, right) Size exclusion chromatography analyses of the licMABs and mAb. (D) SDS-page analysis of purified 
SIRPα-antiCD33 licMAB (1), 2xSIRPα-antiCD33 licMAB (2) and antiCD33 mAb (3) under reducing conditions. Bands corresponding to 
the heavy chain (HC) or light chain (LC) of each molecule are indicated. (E) Melting curves of antiCD33 mAb, SIRPα-antiCD33 licMAB 
and 2xSIRPα-antiCD33 licMAB, determined by fluorescence thermal shift (RFU, Relative Fluorescence Units). The measured melting 
points (Tm) of each molecule are specified. 
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time (Figure 4A). 14.8 ± 3.1% of the molecules were 
internalized after 30 min of incubation, 37.0 ± 3.1% 
after 60 min and 58.8 ± 3.5% after 120 min, which is in 
agreement with data reported previously [31, 32]. 
To confirm the results obtained by flow cytometry, 
confocal microscopy using directly labeled licMABs or 
mAbs was performed. Confocal images showed a clear 
membrane-bound staining for control samples incubated at 
4°C, where internalization does not take place (Figure 4B). 
However, a re-localization of the molecules was observed 
when the sample was incubated at 37°C. After 30 and 60 
min of incubation, SIRPα-antiCD33 licMAB, 2xSIRPα-
antiCD33 licMAB and antiCD33 mAb staining appeared 
on both the cell membrane and intracellular sites and 
after 120 min only low levels of intracellular signal were 
detected due to degradation of the molecules or bleaching 
of the coupled dye in low-pH lysosomal compartments. 
In summary, 2xSIRPα-antiCD33 and SIRPα-antiCD33 
licMABs, as well as antiCD33 mAb, displayed similar 
internalization rates.
LicMABs mediate specific lysis of AML cell lines 
One of the main mechanisms by which IgG1 
antibodies induce the elimination of antibody-bound cells 
is ADCC [2]. Therefore, we hypothesized that licMABs 
(engineered from an IgG1 antibody) would induce ADCC 
of antigen-expressing cells. To test this, calcein-labeled 
MOLM-13 cells were co-incubated with freshly isolated NK 
cells in the presence of increasing licMAB concentrations. 
Figure 3: LicMABs bind strongly to CD33 and weakly to CD47. (A) Quantification of CD33 and CD47 antigens expressed on 
the cell surface of MOLM-13, SEM, CHO_CD33 and CHO_CD47 cell lines assessed with QIFIKIT. Data is displayed as the mean ± SEM 
of four independent experiments. (B) Binding analysis of antiCD33 mAb, SIRPα-antiCD33 licMAB and 2xSIRPα-antiCD33 licMAB to 
different cell lines by flow cytometry detected by a secondary FITC-conjugated antiHuman Fc antibody. The grey line indicates unspecific 
staining of the secondary antibody to the corresponding cells. The experiment was performed three times with similar results. (C) KD 
determination of antiCD33 mAb, SIRPα-antiCD33 licMAB and 2xSIRPα-antiCD33 licMAB on MOLM-13 cells measured by calibrated 
flow cytometry. Mean values and SEM (error bars) of three independent experiments are plotted and KD values are indicated. (D) Percentage 
of MOLM-13 cells or RBCs within the antibody-bound cells. Error bars indicate SEM of three independent experiments with three different 
donors.
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SIRPα-antiCD33 and 2xSIRPα-antiCD33 
licMABs, as well as antiCD33 mAb, efficiently and 
dose-dependently stimulated cytotoxicity of MOLM-13 
cells achieving a maximum specific lysis of 20% at 
concentrations of 1 nM (Figure 5A). The rather low 
maximal specific lysis for this particular cell line is 
consistent with other ADCC studies on MOLM-13 
cells [27, 33]. As a control molecule, we used a human 
IgG1 mAb targeting CD19, a B-cell lymphoma antigen, 
which did not induce killing of MOLM-13 cells due to 
the lack of CD19 expression. However, SIRPα-antiCD19 
licMAB induced cell lysis at high concentrations (100 
nM), probably due to minimal binding of SIRPα to 
CD47 expressed on MOLM-13 cells (Figure 5A). 
Nonetheless, the EC50 value of the CD19-directed 
licMAB (4 nM) was 100-fold higher than the EC50 value of 
the CD33-targeting licMABs (30 pM), clearly underlining 
antigen-specific cytotoxicity (Table 1). 
Next, we investigated the cytotoxic effect of the 
SIRPα domain within the CD33-targeting licMABs by 
ADCC assays using the SEM cell line. SEM cells are 
derived from B-lineage ALL cells and are thus positive 
for CD19 and CD47 but negative for CD33. As effector 
cells, IL-2 expanded NK cells were used. Neither the 
control antiCD33 mAb nor the SIRPα-antiCD33 licMAB 
stimulated killing of the SEM cell line, demonstrating that 
NK cells were not recruited to CD47 positive cells by the 
SIRPα domain of the licMAB (Figure 5B). The 2xSIRPα-
antiCD33 licMAB showed a minor specific lysis at 1 nM, 
indicating a CD47-targeting effect due to increased SIRPα 
quantities. As expected, SIRPα-antiCD19 licMAB and 
antiCD19 mAb induced specific killing of CD19 positive 
SEM cells, reaching maximal specific lysis of 65% at 
concentrations of 1 nM. 
We have demonstrated the capability of licMABs to 
induce NK cell-mediated killing of target cells. However, 
CD33 is not only expressed on AML cells, but also on 
healthy cells from the myeloid lineage [34]. Thus, 
licMABs could potentially be detrimental to healthy cells 
co-expressing CD33 and CD47. Since CD33 expression 
has been described to be much higher on AML cells 
compared to healthy cells [29], we evaluated the ability 
Figure 4: LicMAB molecules internalize upon CD33 binding. (A) Internalization of antiCD33 mAb, SIRPα-antiCD33 licMAB 
and 2xSIRPα-antiCD33 licMAB on MOLM-13 cells assessed by flow cytometry. Percentage of internalized molecules relative to cells 
kept on ice water of three independent experiments is shown (error bars indicate SEM). (B) Directly labeled antiCD33 mAb, SIRPα-
antiCD33 licMAB and 2xSIRPα-antiCD33 licMAB were incubated with MOLM-13 cells either at 4°C or at 37°C for 30, 60 or 120 min 
and internalization was visualized by confocal microscopy (scale bar = 10 µm).
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of licMABs to preferentially target cells expressing high 
levels of CD33 in the presence of low CD33-expressing 
cells. We performed an ADCC assay using a 1:1 mixture 
of MOLM-13 and OCI-AML3 cells, the latter known to 
express lower levels of CD33. LicMABs and antiCD33 
mAb preferentially induced lysis of MOLM-13 cells in 
comparison to OCI-AML3 cells at both concentrations 
evaluated (10 µM and at the EC50), indicating that cells 
expressing high levels of CD33, such as tumor cells, are 
preferentially cleared (Supplementary Figure S2).
Taken together, these results confirm that licMABs 
recruit and activate NK cells upon antigen binding. 
Furthermore, they imply that the endogenous low affinity 
extracellular domain of SIRPα does not function as a 
robust CD47-targeting agent by itself and that the activity 
of licMABs is dominated by high affinity binding to the 
tumor antigen.
Phagocytosis of AML cell lines is enhanced by 
licMABs
The key goal of the engineered licMABs is to inhibit 
the CD47-SIRPα signaling pathway and thus increase 
the phagocytosis of tumor antigen-expressing cells. 
We reasoned that licMABs stimulate phagocytosis by 
delivering an Fc-mediated pro-phagocytic signal to FcRs 
on macrophages and simultaneously disrupt the native 
CD47-SIRPα interaction. To address this experimentally, 
we performed an antibody-dependent cellular phagocytosis 
(ADCP) assay with Macrophage-Colony Stimulator Factor 
(M-CSF) differentiated macrophages and MOLM-13 cells 
by Imaging Flow Cytometry (IFC).
To test the engulfment ability of the M-CSF 
differentiated macrophages, carboxylate microspheres 
were used instead of target cells, achieving a phagocytosis 
of 17.8 ± 2.3%. For negative controls, the ADCP assay 
was performed either at 4ºC, where phagocytosis is 
prevented, or in presence of cytochalasin D, an inhibitor 
of actin polymerization [35]. As expected, phagocytosis 
was prohibited under control conditions (0.6 ± 0.1% and 
1.0 ± 0.3% when incubated at 4°C or with cytochalasin D, 
respectively). 
Importantly, the addition of the antiCD33 licMABs 
and mAb promoted phagocytosis of MOLM-13 cells 
in a concentration-dependent manner (Figure 6A). 
Phagocytosis was significantly enhanced by blocking 
Table 1: EC50 values (pM) obtained for licMABs and mAbs in ADCC assays with MOLM-13 and 
SEM cell lines as target cells
Molecule MOLM-13 SEM
antiCD33 mAb 29.13 n.d.
SIRPα-antiCD33 licMAB 23.0 n.d.
2xSIRPα-antiCD33 licMAB 34.3 111.5
antiCD19 mAb n.d. 33.4
SIRPα-antiCD19 licMAB 4089.0 27.4
n.d., not determined
Figure 5: Specific cytotoxicity of tumor cells is mediated by licMABs. Cytotoxic effects on MOLM-13 cells (A) and SEM cells 
(B) induced by antiCD33 mAb, SIRPα-antiCD33 licMAB, 2xSIRPα-antiCD33 licMAB, antiCD19 mAb and SIRPα-antiCD19 licMAB 
were analyzed by calcein release assays and plotted as a dose-response curve (n = 4, error bars = SEM). 
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the CD47-SIRPα axis, with respect to the control 
antiCD33 antibody, for the 2xSIRPα-antiCD33 licMAB 
at concentrations higher than 0.1 nM and for the SIRPα-
antiCD33 licMAB at 0.1 nM and 100 nM (Figure 6A, 6B). 
The ability of licMABs to enhance phagocytosis of AML 
cell lines was confirmed using another CD33 and CD47 
positive AML cell line (OCI-AML3) as target cells 
(Supplementary Figure S3).
In summary, these results suggest that licMABs 
interfere with the CD47-SIRPα axis upon tumor 
antigen binding, thus blocking the inhibitory signal in 
macrophages and enhancing specific phagocytosis of 
target AML cell lines.
LicMABs efficiently promote elimination of 
primary, patient-derived AML cells
After determining the functionality of licMABs 
to mediate killing and phagocytosis of established AML 
cell lines, we sought to evaluate the cytotoxicity of these 
molecules in primary patient-derived AML cells in a non-
autologous setting. For that purpose, primary NK cells 
from healthy donors were co-incubated for 24 h ex vivo 
with AML patient cells and licMABs and analyzed by flow 
cytometry.
SIRPα-antiCD33 and 2xSIRPα-antiCD33 licMABs 
successfully triggered NK cell-mediated cytotoxicity of 
AML patient cells. Notably, licMAB molecules induced 
significantly improved killing of AML cells compared 
with antiCD33 mAb, presumably due to avidity binding 
of SIRPα domains (Figure 7). Although there was a 
clear overall tendency in the response of analyzed 
patient samples, individual differences were observed, 
demonstrating a relevant degree in heterogeneity between 
AML patients (Supplementary Figure S4). Interestingly, 
patients 4 and 6 extremely benefited from licMABs 
antitumor activity, achieving a 4.1- and 38.4-fold elevated 
specific lysis of primary AML cells, respectively, in 
comparison to the control antiCD33 mAb. Furthermore, 
patients 7 and 9 profited from the second SIRPα domain 
by obtaining a 2.5- and 4.2-fold increased specific lysis, 
respectively, with respect to the SIRPα-antiCD33 licMAB.
Taken together, these results show that licMABs 
efficiently induce NK cell-mediated killing of primary 
AML patient cells ex vivo. 
DISCUSSION
In this study we report the development of licMABs, 
novel therapeutic agents that combine specific tumor 
antigen binding, Fc-mediated immune cell recruitment 
and activation, and simultaneous disruption of the 
CD47-SIRPα axis. LicMABs, generated by grafting the 
endogenous N-terminal extracellular domain of SIRPα 
onto an IgG1 antibody targeting the AML antigen 
CD33, successfully induced NK cell-mediated killing 
of AML cell lines and primary AML patient cells and 
enhanced phagocytosis of AML cell lines. The antitumor 
activity triggered by these molecules identifies them as a 
promising therapeutic approach for AML. 
Previous studies analyzed CD47 expression on AML 
cells by comparing its expression levels on AML LSCs 
with respect to hematopoietic stem cells (HSCs) from 
healthy donors and concluded that CD47 is overexpressed 
on AML LSCs [8]. Here, we further characterized 
CD47 expression levels on AML patient samples and 
Figure 6: LicMAB molecules enhanced phagocytosis of MOLM-13 cells. (A) Phagocytosis of MOLM-13 cells stimulated by 
antiCD33 mAb, SIRPα-antiCD33 licMAB and 2xSIRPα-antiCD33 licMAB at different concentrations was evaluated by imaging flow 
cytometry. Error bars indicate the SEM of three independent experiments using three different donors and statistical significance was 
calculated with a t-test with Welch’s correction (p-value < 0.05*, < 0.01**). (B) Representative images of PKH67 (macrophages) and 
PKH26 (MOLM-13) positive single cells that were defined as phagocytic events obtained by imaging flow cytometry (BF, bright field). 
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demonstrated that CD47 is highly expressed on both 
the bulk AML cells and AML LSCs. Moreover, CD47 
expression on AML cells did not differ between initial 
diagnosis of the disease or at time of relapse. These results 
imply that therapies that block the CD47-SIRPα axis, as 
licMABs, target bulk AML cells as well as AML LSCs. 
Most importantly, such therapies would thus be suited for 
not only initially diagnosed, but also relapsed patients, for 
whom there is no current standard treatment [36]. 
The blockade of the CD47-SIRPα signaling pathway 
has recently been investigated as a therapeutic tool, and 
several approaches to disrupt the CD47-SIRPα axis, 
including mAbs against CD47 and CD47-antagonists, 
have been shown to stimulate clearance of tumor cells 
by phagocytosis [9–13, 17, 37]. However, due to the 
ubiquitous expression of CD47, high affinity binding 
agents may cause undesired toxicity to healthy cells. 
Furthermore, cells expressing CD47, such as RBCs, 
might function as an antigen sink and could prevent 
CD47-targeting molecules from binding to tumor cells 
in vivo. To avoid direct targeting of CD47 but still 
interfere with the CD47-SIRPα signaling pathway, we 
took advantage of the naturally occurring weak interaction 
between CD47 and SIRPα. We therefore hypothesized 
that the engraftment of the endogenous SIRPα domain, 
which has a low affinity towards CD47 [16], onto a 
mAb targeting CD33 with high affinity, would result 
in a molecule that specifically recognizes and binds to 
AML cells via CD33 and locally blocks the CD47-SIRPα 
pathway. The resulting licMAB would induce killing and 
phagocytosis of tumor cells while avoiding systemic side 
effects. 
A similar approach was recently published, and the 
respective SIRPabodies, which combine an antiCD20 
mAb and the endogenous SIRPα domain, were shown 
to bind CD20 and CD47 on dual expressing cells, 
reduce tumor burden and prolong survival in xenograft 
lymphoma mouse models [17]. In this case, a single SIRPα 
extracellular domain was fused to the IgG1 heavy chain N- 
or C-terminal, whereas in the case of licMABs, a single or 
tandem SIRPα domain was fused to the N-terminus of the 
light chain. The fusion of the extracellular SIPRα domain 
to the N-terminus of the light or heavy chain generates a 
native N-terminus of the SIRPα part, but may interfere 
with the Complementarity-Determining Regions (CDRs) 
of the parental antibody. Alternatively, the fusion of the 
SIRPα domain to the C-terminus of the light or heavy 
chain most likely does not compromise the antibody’s 
CDRs, but might impact CD47 binding. Therefore, the 
position of the SIRPα domain on SIRPα-antibody fusion 
proteins needs to be further optimized in order to achieve 
best antitumor effects.
Figure 7: LicMABs induced NK cell-mediated cytotoxicity of AML patient samples. Cytotoxicity of primary AML patient 
cells triggered by antiCD33 mAb, SIRPα-antiCD33 licMAB and 2xSIRPα-antiCD33 licMAB at a concentration of 10 nM was analyzed by 
determining the percentage of remaining CD33 or CD123 positive cells by flow cytometry. Error bars indicate the SEM of 9 different AML 
patient samples. Statistical differences were assessed using the Wilcoxon test (p-value < 0.05*, < 0.01**). 
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Binding analyses performed in the present study 
demonstrate that licMABs bind to CD33 with high affinity 
and, consistent with our hypothesis, interact weakly with 
cells expressing CD47 but not CD33. This binding to 
CD47, however, correlated with surface expression of 
this molecule. Since CD47 is overexpressed on cancer 
cells with respect to normal cells, we propose that the 
SIRPα domain of the licMAB would not bind to normal 
cells expressing CD47 but facilitate the targeting of dual 
antigen-expressing tumor cells led by high affinity binding 
to CD33. This specific feature is of utmost importance in 
the context of circulating RBCs expressing CD47, which 
provide a large antigen sink and a high risk for toxicity as 
CD47 expression prevents clearance of RBCs in vivo [38]. 
Consequently, the binding properties of licMABs enable 
them to selectively bind to CD33-expressing tumor cells 
in the presence of excess of RBCs expressing CD47, thus 
overcoming the antigen sink that RBCs may represent. 
Additional binding analyses underline the hypothesis that 
the blockade of the CD47-SIRPα axis can be modulated 
by varying the amount of SIRPα domains in a licMAB. 
Taken together, the binding properties of licMABs enable 
these molecules to discriminate between CD33 negative 
and CD47 positive healthy cells, and CD33 and CD47 
double positive tumor cells, and to selectively bind to the 
latter, avoiding undesired side effects.
Moreover, based on preferential lysis studies, we 
suggest that licMABs are preferentially directed to cells 
expressing high levels of CD33 on their surface, even in 
the presence of low CD33-expressing cells, which is in 
agreement with previous findings. For instance, a clear 
relation between CD33 expression and the efficacy of 
Gemtuzumab Ozogamicin (GO, a drug-conjugated antibody 
targeting CD33) was shown in vitro and in vivo, indicating 
that a higher cytotoxicity is correlated with higher numbers 
of CD33 expressed on target cells [32, 39]. Furthermore, a 
study that characterized a CD33-CD3 BiTE molecule (AMG 
330) has demonstrated preferential lysis of cells with high 
CD33 expression compared to cells with low expression 
of CD33 [29]. These evidences support our hypothesis 
that licMABs target and induce clearance of high CD33 
expressing cells, such as AML cells, and only have a mild 
effect on healthy cells expressing lower levels of CD33.
Even though blockade of the CD47-SIRPα axis 
interferes with inhibition of phagocytosis, studies using an 
engineered high affinity SIRPα domain, which functions 
as a CD47-antagonist. They demonstrated that an 
Fc-mediated pro-phagocytic stimulus is required in order 
to induce active phagocytosis of tumor cells [37]. Along 
similar lines, disruption of the CD47-SIRPα axis has been 
shown to synergize with the Fc-mediated pro-phagocytic 
stimulus of a mAb targeting a tumor antigen, such as 
rituximab, an antiCD20 mAb [12]. In order to benefit 
from the combination of the blockade of the CD47-SIRPα 
axis and a Fc-mediated stimulus in one single molecule, 
a bispecific antibody targeting CD20 and CD47 was 
generated [13]. CD20/CD47 bispecific antibodies 
reduced lymphoma burden and extended survival of 
NHL-engrafted mice, hence recapitulating the synergistic 
effects of antiCD47 and antiCD20 combination therapy. 
The results obtained with licMABs in this work are in 
agreement with those achieved by Piccione and coworkers 
[13, 17]. LicMAB molecules promote tumor specific 
phagocytosis by combining two pro-phagocytic signals: 
(1) blockade of the CD47-SIRPα signaling pathway by 
the endogenous SIRPα domain and (2) engagement of 
the FcRs by the Fc domain. Thus, we demonstrate that 
licMABs significantly enhanced phagocytosis of tumor 
cells with respect to the antiCD33 mAb. 
Additionally, we proved that the IgG1 Fc domain 
of the licMAB is able to recruit and activate NK cells, 
therefore inducing cytotoxicity to targeted cells. Although 
unintended targeting to CD47 single positive cells might 
be supported by increased concentrations of licMABs 
or by attaching additional SIRPα domains, our results 
suggest a wide “therapeutic window”, i.e. a concentration 
range, where licMABs strongly favor elimination of 
tumor antigen-expressing cells and do not compromise 
cells that do not express the targeted tumor antigen. We 
consequently argue that with this approach, an undesired 
binding to CD47 expressed on healthy cells can be 
substantially reduced, lowering possible cytotoxic side 
effects. Studies with primary, patient-derived AML cells 
demonstrated that licMABs efficiently recruit and activate 
NK cells, thus inducing clearance of AML patient cells 
ex vivo. Notably, licMABs enhanced cytotoxicity of 
patient-derived AML cells with respect to the antiCD33 
mAb in 7 out of 9 samples evaluated. Consistent with our 
hypothesis, increasing the local SIRPα concentration by 
adding a second SIRPα Ig V-like domain on the licMAB 
was beneficial for some patients. The favorable effects of 
the second SIRPα domain, however, cannot be generalized 
due to heterogeneity within patient samples. Hence, the 
optimal licMAB format has to be determined for each 
patient individually.
Besides the pro-phagocytic stimulus and NK cell 
cytotoxicity delivered by the Fc domain of the licMAB, 
we predict an additional tumor clearance effect by 
adaptive immune cells. After tumor cell phagocytosis, 
antigen-presenting cells (APCs), such as macrophages and 
dendritic cells (DCs), present tumor antigens to T cells 
triggering an adaptive immune response [40]. Therefore, 
stimulation of tumor cell phagocytosis by blocking the 
CD47-SIRPα axis enhances antigen-presentation and 
ultimately leads to increased tumor elimination [41, 42]. 
This hypothesis is supported by previous studies showing 
that an antiCD47 mAb induces cross-priming of CD8 
positive T cells by macrophages and DCs, which results 
in effective antitumor T cell responses [41, 43]. 
A minor drawback of the CD33-targeting licMABs 
is the CD33-dependent internalization, which was 
previously described for other CD33-targeting antibody 
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derivatives [31, 32]. Antibody-drug conjugated molecules 
targeting CD33, such as Gemtuzumab ozogamicin (GO) 
or SGN-CD33A have been developed to profit from 
CD33 internalization in order to deliver a drug into the 
tumor cell [24, 31]. Since the mode of action of licMAB 
molecules is based on the recruitment of immune 
effector cells, their internalization might hamper the 
immune response against the target tumor cell. Although 
licMABs induced cytotoxicity and phagocytosis of CD33 
positive tumor cells, antitumor immune responses might 
be even greater if internalization would not occur. As 
no CD33-dependent internalization has been reported 
for monovalent agents, such as for AMG 330 [44], a 
strategy to reduce CD33-dependent internalization of 
licMABs is to target CD33 with only one binding site. 
Therefore, an antiCD33/SIRPα bispecific antibody, 
containing a single binding arm targeting CD33 and the 
endogenous N-terminal SIRPα domain on the other arm, 
has been developed and is currently under investigation. 
Although the resulting molecule would not retain the 
favorable avidity effects of a mAb and may therefore 
have a lower affinity towards CD33, monovalent 
targeting of CD33 might reduce internalization and this 
may enhance elimination of tumor cells. Furthermore, 
a trispecific molecule consisting of (1) a single chain 
variable fragment (scFv) binding to a tumor antigen, (2) 
the endogenous SIRPα domain to block the CD47-SIRPα 
signaling pathway and (3) a scFv to trigger recruitment 
and activation of effector cells may recapitulate the 
antitumor activity of SIRPα-antiCD33 licMAB and not 
induce CD33 internalization. Notably, this molecule 
would be smaller in size than the licMAB, which 
could be beneficial when transferring the CD47-SIRPα 
blockade to solid tumors, as tumor penetration appears 
to be a challenging issue. Another approach to avoid 
licMAB’s internalization would be to target another 
antigen with reduced internalization, such as CD123, 
which is also a validated target antigen overexpressed on 
AML LSCs [45], and retains a very low internalization 
rate upon binding [46]. Taken together, CD33-dependent 
internalization of licMABs could be overcome by 
different strategies, which should be further explored in 
order to have a maximal effect on tumor clearance.
In summary, the novel therapeutic agents called 
licMABs promoted NK cell-mediated cytotoxicity on 
CD33 and CD47 double positive AML cell lines and 
primary, patient-derived AML cells and did not trigger 
depletion of CD33 negative, CD47 positive cells. 
Moreover, by combining the recruitment and activation 
of FcRs via the antibody Fc domain and the blockade of 
CD47-SIRPα interaction by the endogenous low affinity 
CD47-antagonistic SIRPα domain, licMAB molecules 
significantly enhanced phagocytosis of tumor cells. 
Collectively, licMAB’s characteristics and antitumor 
properties establish these molecules as promising 
therapeutic tools for the treatment of AML.
MATERIALS AND METHODS
SIRPα-antiCD33 licMAB, 2xSIRPα-antiCD33 
licMAB and antiCD33 mAb construction and 
production
The antiCD33 variable light (VL) and variable 
heavy (VH) (clone hP67.6) were generated using custom 
gene synthesis (GeneArt, Thermo Fisher Scientific). The 
antiCD33 VL was subcloned into the pFUSE2-CLIg-hk 
vector (InvivoGen) and the antiCD33 VH into the 
pFUSE-CHIg-hG1 vector (InvivoGen). To generate the 
SIRPα-antiCD33 licMAB, the N-terminal Ig-like V-type 
domain of SIRPα (residues 1-120) was synthesized using 
custom gene synthesis (GeneArt, Thermo Fisher Scientific) 
and subcloned into the N-terminus of the antiCD33 light 
chain (LC) together with a (G4S)4 linker. A second SIRPα-
(G4S)4 linker cassette was cloned N-terminal of the SIRPα-
antiCD33 LC to obtain the 2xSIRPα-antiCD33 light chain. 
A cassette of SIRPα-(G4S)2 linker, containing a PreScission 
protease cleavage site (PreSc) at the C-terminus, was 
cloned N-terminal of the antiCD33 LC to generate 
a SIRPα-PreSc-antiCD33 antibody with a cleavable 
SIRPα. The corresponding plasmids were transfected into 
Expi293F cells (Thermo Fisher Scientific) according to 
the manufacturer’s protocol. After five to seven days, the 
cell culture supernatant was harvested and licMABs were 
purified by protein A affinity chromatography. To obtain 
the antiCD33 mAb, SIRPα-PreSc-antiCD33 was incubated 
with PreScission protease for 6 h followed by a second 
round of protein A affinity chromatography. LicMABs and 
mAb were dialyzed against Phosphate Buffered Saline 
(PBS) and size exclusion chromatography (SEC) of the 
purified molecules was performed using a Superdex 200 
increase 10/300 column (GE Healthcare Life Sciences, 
Little Chalfont, Buckinghamshire, United Kingdom). 
LicMABs and mAb were then analyzed by 4–20 % 
SDS-PAGE (Expedeon) under reducing conditions and 
visualized by Coomassie Brilliant Blue staining. Protein 
concentration was measured with a spectrophotometer 
(NanoDrop, GE Healthcare Life Sciences, Little Chalfont, 
Buckinghamshire, United Kingdom) and aliquots were 
stored at –80°C.
Cell lines
The MOLM-13 and OCI-AML3 cell lines 
were purchased from the ‘Deutsche Sammlung 
von Mikroorganismen und Zellkulturen’ (DSMZ, 
Leibniz-Institut DSMZ, Braunschweig, Germany), the 
SEM cell line from the American Type Culture Collection 
(ATCC, Rockville, MD, USA) and the Flp-INTM-CHO 
cell line from Thermo Fisher Scientific (Waltham, 
Massachusetts, USA). MOLM-13 cells were cultured 
in RPMI 1640 + GlutaMAX (Gibco, Thermo Fisher 
Scientific) and supplemented with 20% fetal bovine 
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serum (FBS, Gibco, Thermo Fisher Scientific). SEM 
and OCI-AML3 cell lines were grown in RMPI 1460 + 
GlutaMAX (Thermo Fisher Scientific) with 10% FBS. 
The Flp-INTM-CHO cell line was engineered to stably 
express human CD33 (CHO_CD33) or human CD47 
(CHO_CD47) and maintained in selection media (Ham´s 
F-12 (Biochrom), 10% FBS and 550 µg/mL hygromycin 
B gold (InvivoGen)). The Expi293F cell line was obtained 
from Thermo Fisher Scientific and cultured in Expi293 
Expression Medium.
Patients
After written informed consent in accordance 
with the Declaration of Helsinki and approval by the 
Institutional Review Board of the Ludwig-Maximilians-
Universität (Munich, Germany), peripheral blood (PB) or 
bone marrow (BM) samples were collected from healthy 
donors (HDs) and patients with AML at initial diagnosis 
or relapse. PB or BM samples from AML patients were 
cryoconserved at ≤ –80°C in 80% FCS and 20% dimethyl 
sulfoxide (Serva Electrophoresis) until usage. PB from 
HDs was obtained on the day of the experiment.
For CD47 expression analysis, PB or BM samples 
from AML patients (n = 213) at initial diagnosis (n = 182) 
or relapse (n = 31) were collected between January 2014 
and May 2016. AML was diagnosed according to the 
FAB (French-American-British) classification by the 
Laboratory of Leukemia Diagnostics of the Department 
of Internal Medicine III of the Klinikum der Universität 
München [47]. 
Preparation of RBCs, peripheral blood 
mononuclear cells (PBMCs), NK cells and 
monocytes from whole human blood
RBCs were isolated from HDs PB by centrifugation 
and subsequently washed with RBC’s wash buffer, as 
described previously [48]. PBMCs from AML patients and 
HDs were separated from PB by density gradient using the 
Biocoll separating solution (Biochrom), according to the 
manufacturer’s protocol. NK cells were either expanded 
ex vivo by culturing PBMCs under IL-2 stimulus as 
described previously [49] or freshly isolated by magnetic 
separation using a human NK cell isolation kit (MACS 
Miltenyi Biotech) according to the manufacturer’s 
protocol. Monocytes were isolated from PBMCs by 
magnetic separation with human CD14 MicroBeads 
(MACS Miltenyi Biotech) following the manufacturer’s 
instructions.
Thermal stability
The thermal stability of the licMABs and mAb was 
determined by fluorescence thermal shift assays using the 
CFX96 Touch Real-Time PCR Detection System (Bio-
Rad, Munich, Germany)  [50]. 10 µg of protein containing 
1x SYPRO Orange (Thermo Fisher Scientific) were 
measured using FAM and SYBR Green I filter pairs. 
Detection of binding by flow cytometry
If not otherwise stated, flow cytometry analyses 
were performed on a Guava easyCyte 6HT instrument 
(Merck Millipore, Billerica, Massachusetts, USA) and 
data was plotted with GuavaSoft software version 3.1.1 
(Merck Millipore, Billerica, Massachusetts, USA). 
MOLM-13, SEM, CHO_CD33 and CHO_CD47 
cells were stained with 15 µg/ml of licMABs or mAb 
followed by staining with a secondary FITC antiHuman 
IgG Fc antibody (clone HP6017, BioLegend). The median 
fluorescence intensity (MFI) ratio was calculated dividing 
MFI of the antibody by the MFI of the isotype control.
Quantitative determination of cell surface 
antigens
The QIFIKIT kit (Dako) was utilized to quantify 
antigen surface expression following the manufacturer’s 
instructions [51]. Briefly, cells were incubated with 
saturating concentrations of primary mouse antibody 
against human CD33 or CD47 (clone P67.7, BioLegend 
and clone CC2C6, BioLegend, respectively). Cells and 
QIFIKIT beads were stained in parallel with polyclonal 
Goat antiMouse FITC-conjugated (QIFIKIT, DAKO) at 
saturating concentrations. The MFI was plotted to obtain 
a calibration curve, which was used to interpolate the MFI 
values of the samples and obtain the numbers of antigenic 
sites on the cells.
KD determination
CD33 equilibrium binding constants (KD, as an 
avidity measurement) of the licMABs and mAb were 
determined by calibrated flow cytometry analyses as 
previously described [52]. Briefly, MOLM-13 cells were 
incubated with licMABs or mAb in concentrations ranging 
from 0.01 to 15 µg/ml and stained with a FITC antiHuman 
IgG Fc (clone HP6017, BioLegend) secondary antibody 
by flow cytometry. The instrument was calibrated with 
3.0–3.4 µm Rainbow Calibration particles of 8 peaks 
(BioLegend), the maximum MFI value was set to 100% 
and all data points were normalized accordingly. The 
assay was performed in quadruplicates and the values 
were analyzed by non-linear regression using a one-site 
specific binding model.
RBCs competition assay
MOLM-13 were stained with PKH26 (Sigma-
Aldrich) following the manufacturer’s instructions. Next, 
labeled MOLM-13 cells were mixed with freshly isolated 
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RBCs in 5-, 10- or 20-fold excess and incubated with 
15 µg/ml of licMABs, antiCD33 mAb or antiCD47 (clone 
B6H12, eBioscience). Antibody binding was detected with a 
secondary FITC antiHuman IgG Fc antibody (clone HP6017, 
BioLegend) by flow cytometry. The MFI of antibody-bound 
cells (FITC positive) was obtained and the MFI ratio of the 
sample containing licMABs, mAbs or the IgG1 isotype 
control (clone ET901, Biolegend) divided by the MFI value 
of the control sample containing uniquely the secondary 
antibody was calculated. The percentage of MOLM-13 cells 
(PKH26 positive) or RBCs (PKH26 negative) within the 
antibody-bound cells was determined. Single replicates from 
3 different donors were averaged together (mean ± SEM).
Internalization assay by flow cytometry
MOLM-13 cells were incubated with 15 µg/ml 
of licMABs or mAb either on ice-cold water for 120 
min (to prevent internalization) or at 37°C for 30, 60 or 
120 min. Cells were then washed with ice-cold FACS 
buffer and antibodies remaining on the surface were 
detected by staining with FITC antiHuman IgG Fc 
(clone HP6017, BioLegend). To define the background 
fluorescence, MOLM-13 cells were directly stained 
with the secondary antibody. The internalization was 
calculated as follows:
Internalization (%) =
(MFI4°C) – MFIbackground) – (MFI37°C) – MFIbackground) × 100
(MFI4°C – MFIbackground)
Internalization assay by confocal microscopy
MOLM-13 cells were cultured on a poly-L-lysine 
(Sigma-Aldrich) coated 96-well plate. Subsequently, 
cells were incubated with 15 µg/ml of licMABs or 
mAb directly labeled with Alexa Fluor 488 (Antibody 
Labeling Kit, Thermo Fisher Scientific), either on 
ice-cold water for 120 min or at 37°C for 30, 60 or 
120 min. Then, cells were fixed and permeabilized in 
20 mM PIPES pH 6.8, 4% formaldehyde, 0.2% Triton 
X-100, 10 mM EGTA, 1 mM MgCl2 at room temperature 
for 10 min, followed by incubation in blocking solution 
(3% bovine serum albumin in PBS). Cells were washed 
three times with 0.05% Tween-20 in PBS and stored 
in PBS until examination on a fully automated Zeiss 
inverted microscope (AxioObserver Z1) equipped with 
a MS-2000 stage (Applied Scientific Instrumentation, 
Eugene, Orlando, USA), a CSU-X1 spinning disk 
confocal head (Yokogawa) and a LaserStack Launch with 
selectable laser lines (Intelligent Imaging Innovations, 
Denver, CO). Images were acquired using a CoolSnap 
HQ camera (Roper Scientific, Planegg, Germany), a 
63x oil objective (Plan Neofluoar 63x/1.25) and the 
Slidebook software (version 6.0; Intelligent Imaging 
Innovations, Denver, CO). Images were processed with 
Adobe Photoshop CS4 (Adobe Systems, Mountain View, 
California, USA).
CD47 expression in AML patients
CD47 expression levels on primary AML samples 
were analyzed by flow cytometry (Navios, Beckman 
Coulter, Krefeld, Germany) using the mAbs CD47 
(clone 472603, R&D), CD45 (clone J33, Beckman 
Coulter), CD34 (clone 581, Beckman Coulter) and 
CD38 (clone LS198-4-3, Beckman Coulter) and the 
corresponding isotype controls. Bulk AML cells were 
identified by limiting the analysis of primary AML sample 
material to SSClow/CD45dim cells. LSCs were defined 
as a CD34+/CD38− subgroup of SSClow/CD45dim cells. 
As a measure for CD47 intensity, CD47 MFI ratio was 
calculated using FlowJo software (Version 9.6, Tree Star 
Inc., Ashland, Oregon).
Antibody-dependent cellular cytotoxicity 
(ADCC) and preferential killing assays
Target cells (MOLM-13 or SEM) were labeled 
with calcein AM (Thermo Fisher Scientific) according 
to manufacturer’s protocol. Calcein-labeled target cells 
were incubated with freshly isolated or IL-2 expanded 
NK cells in an effector-to-target (E:T) ratio of 2:1 
and licMABs or mAb at different concentrations for 4 
h. Target cells were cultured in 10% Triton X-100 to 
assess the maximum unspecific lysis. Calcein release 
was measured by fluorescence intensity with an Infinite® 
M100 plate reader instrument (TECAN, Männedorf, 
Switzerland) and specific lysis was calculated as 
follows:




Averaged specific lysis of triplicates or 
quadruplicates were plotted according to a dose-response 
curve and analyzed using the integrated four parameter 
non-linear fit model. 
To assess the preferential killing of licMABs, 
an ADCC assay was performed with a 1:1 mixture of 
MOLM-13 and OCI-AML3 cells as target cells. Two 
assays, one containing Calcein-labeled MOLM-13 cells 
and unstained OCI-AML3 cells and the other unstained 
MOLM-13 cells and Calcein-labeled OCI-AML3 cells 
were executed in parallel using the same freshly isolated 
NK cells. Preferential killing was evaluated using 
licMABs and antiCD33 mAb at concentrations of 10 
µM or the previously described EC50 and specific lysis 
was measured and calculated as mentioned above. This 
experiment was repeated three times using three different 
donors and mean and SEM values were plotted.
Antibody-dependent cellular phagocytosis 
(ADCP)
Phagocytosis assay was performed as described 
previously [53]. Briefly, isolated monocytes were 
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stained with PKH67 (Sigma-Aldrich) according to 
the manufacturer’s instructions and differentiated 
to macrophages by 20 ng/ml Macrophage-Colony 
Stimulator Factor (M-CSF) (R&D Systems) in 
X-VIVO 10 medium (Lonza) supplemented with 10% 
autologous serum. MOLM-13 cells were stained with 
PKH26 (Sigma-Aldrich) following the manufacturer’s 
instructions and incubated in a 1:2 E:T ratio with 
licMABs or mAb concentrations ranging from 0.01 
nM to 100 nM for 2 h. Polybead® Carboxylate Red-
Dyed Microspheres of 6 μm (Polysciences) were used 
as a positive control and incubation either at 4°C 
or  at 37°C in the presence of 10 µM Cytochlasin D 
(Sigma-Aldrich) served as a negative control. Cells 
were harvested, measured by imaging flow cytometry 
using an ImageStream®X Mark II instrument (Merck 
Millipore, Billerica, Massachusetts, USA) and analyzed 
with IDEAS® and INSPIRE® Software (Merck Millipore, 
Billerica, Massachusetts, USA). The maximum 
phagocytosis value was set to 100% and all data points 
were normalized accordingly. Mean values and standard 
errors of triplicates were calculated and plotted.
Antibody-dependent cellular cytotoxicity in 
primary AML patient samples
Ex vivo expanded primary AML cells of 9 
different patients were co-cultured with freshly isolated 
healthy donor NK cells, at an E:T ratio of 5:1 in an 
ex vivo long term culture system as described by 
Krupka and coworkers [29, 54]. Antibodies were added 
at a final concentration of 10 nM. After 24 hours, 
cells were harvested, stained for CD16 (clone B73.1), 
CD56 (clone HCD 56), CD33 (clone WM53) and in 
concrete cases CD123 (clone 6H6; all antibodies from 
Biolegend) and analyzed by flow cytometry with a BD 
LSR II (Becton Dickinson, Heidelberg, Germany). The 
percentage of residual CD33 or CD123 positive cells 
in treated cultures relative to control cultures was used 
to determine licMAB-mediated cellular cytotoxicity. 
Patient characteristics are summarized in Supplementary 
Table S1.
Plotting and statistical analysis
Unless stated otherwise, data was analyzed and 
plotted with GraphPad Prism version 6.00 for Windows 
(GraphPad Software, La Jolla, California, USA).
Differences in CD47 expression on AML samples 
were calculated using the Mann-Whitney U test. Statistical 
differences in phagocytosis were assessed by an unpaired, 
parametric Student’s t-test with Welch correction and 
statistical differences of patient responses were assessed 
by the Wilcoxon test. Statistical significance was 
considered for p-value < 0.05 (*), < 0.01 (**), < 0.001 
(***) and < 0.0001 (****).
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